Enhancement of the immunoregulatory potency of mesenchymal stromal cells by treatment with immunosuppressive drugs

Dominici, 2006, Minimal criteria for defining multipotent mesenchymal stromal cells, Cytotherapy, 8, 315, 10.1080/14653240600855905 Bartholomew, 2002, Mesenchymal stem cells suppress lymphocyte proliferation in vitro and prolong skin graft survival in vivo, Exp Hematol, 30, 42, 10.1016/S0301-472X(01)00769-X Tse, 2003, Suppression of allogeneic T-cell proliferation by human marrow stromal cells: implications in transplantation, Transplantation, 75, 389, 10.1097/01.TP.0000045055.63901.A9 Caplan, 2011, The MSC: An Injury Drugstore, Cell Stem Cell, 9, 11, 10.1016/j.stem.2011.06.008 Bernardo, 2009, Mesenchymal Stromal Cells: A Novel Treatment Modality for Tissue Repair, Ann N.Y Acad Sci, 1176, 101, 10.1111/j.1749-6632.2009.04607.x Murphy, 2013, Mesenchymal stem cells: environmentally responsive therapeutics for regenerative medicine, Exp Mol Med, 45, e54, 10.1038/emm.2013.94 Bartosh, 2013, Dynamic Compaction of Human Mesenchymal Stem/Precursor Cells Into Spheres Self-Activates Caspase-Dependent IL1 Signaling to Enhance Secretion of Modulators of Inflammation and Immunity (PGE2, TSG6, and STC1), Stem Cells, 31, 2443, 10.1002/stem.1499 Franquesa, 2013, Mesenchymal Stem Cells in Solid Organ Transplantation (MiSOT) Fourth Meeting: lessons learned from first clinical trials, Transplantation, 96, 234, 10.1097/TP.0b013e318298f9fa Le Blanc, 2012, Multipotent mesenchymal stromal cells and the innate immune system, Nat Rev Immunol, 12, 383, 10.1038/nri3209 Ball, 2013, Multiple infusions of mesenchymal stromal cells induce sustained remission in children with steroid-refractory, grade III-IV acute graft-versus-host disease, Br J Haematol, 163, 501, 10.1111/bjh.12545 Kurtzberg, 2014, Allogeneic human mesenchymal stem cell therapy (remestemcel-L, Prochymal) as a rescue agent for severe refractory acute graft-versus-host disease in pediatric patients, Biol Blood Marrow Transplant, 20, 229, 10.1016/j.bbmt.2013.11.001 Lee, 2009, Intravenous hMSCs improve myocardial infarction in mice because cells embolized in lung are activated to secrete the anti-inflammatory protein TSG-6, Cell Stem Cell, 5, 54, 10.1016/j.stem.2009.05.003 Ranganath, 2012, Harnessing the mesenchymal stem cell secretome for the treatment of cardiovascular disease, Cell Stem Cell, 10, 244, 10.1016/j.stem.2012.02.005 Yeo, 2013, Mesenchymal stem cell: an efficient mass producer of exosomes for drug delivery, Adv Drug Deliv Rev, 65, 336, 10.1016/j.addr.2012.07.001 Guilloton, 2012, Mesenchymal stromal cells orchestrate follicular lymphoma cell niche through the CCL2-dependent recruitment and polarization of monocytes, Blood, 119, 2556, 10.1182/blood-2011-08-370908 Kolluri, 2013, Mesenchymal stem cells as vectors for lung cancer therapy, Respiration, 85, 443, 10.1159/000351284 Levy, 2013, mRNA-engineered mesenchymal stem cells for targeted delivery of interleukin-10 to sites of inflammation, Blood, 122, 23, 10.1182/blood-2013-04-495119 Liu, 2013, Comparison of drug and cell-based delivery: engineered adult mesenchymal stem cells expressing soluble tumor necrosis factor receptor II prevent arthritis in mouse and rat animal models, Stem Cells Transl Med, 2, 362, 10.5966/sctm.2012-0135 Girdlestone, 2009, Efficient expansion of mesenchymal stromal cells from umbilical cord under low serum conditions, Cytotherapy, 11, 1, 10.1080/14653240903079401 Dietz, 2006, A novel source of viable peripheral blood mononuclear cells from leukoreduction system chambers, Transfusion, 46, 2083, 10.1111/j.1537-2995.2006.01033.x Cutler, 2010, Umbilical Cord-derived Mesenchymal Stromal Cells Modulate Monocyte Function to Suppress T cell proliferation, J Immunol, 185, 6617, 10.4049/jimmunol.1002239 Ali, 2012, Xenogeneic Graft-versus-Host-Disease in NOD-scid IL-2Rγnull Mice Display a T-Effector Memory Phenotype, PLoS ONE, 7, e44219, 10.1371/journal.pone.0044219 Moncrieffe, 2008, The influence of CD4 T-cell subsets on control of CD4 T-cell mediated graft-versus-host disease, Immunology, 125, 459, 10.1111/j.1365-2567.2008.02866.x Hoogduijn, 2008, Susceptibility of Human Mesenchymal Stem Cells to Tacrolimus, Mycophenolic Acid, and Rapamycin, Transplantation, 86, 1283, 10.1097/TP.0b013e31818aa536 Trepanier, 1998, Rapamycin: distribution, pharmacokinetics and therapeutic range investigations: an update, Clin Biochem, 31, 345, 10.1016/S0009-9120(98)00048-4 Reichardt, 2008, Impact of Mammalian Target of Rapamycin Inhibition on Lymphoid Homing and Tolerogenic Function of Nanoparticle-Labeled Dendritic Cells following Allogeneic Hematopoietic Cell Transplantation, J Immunol, 181, 4770, 10.4049/jimmunol.181.7.4770 Li, 2011, Interaction of calcineurin with substrates and targeting proteins, Trends Cell Biol, 21, 91, 10.1016/j.tcb.2010.09.011 Orange, 2013, Dendritic cells loaded with FK506 kill T cells in an antigen-specific manner and prevent autoimmunity in vivo, eLife, 2, e00105, 10.7554/eLife.00105 Ge, 2009, Infusion of mesenchymal stem cells and rapamycin synergize to attenuate alloimmune responses and promote cardiac allograft tolerance, Am J Transplant, 9, 1760, 10.1111/j.1600-6143.2009.02721.x Wang, 2013, Rapamycin-treated human endothelial cells preferentially activate allogeneic regulatory T cells, J Clin Invest, 123, 1677, 10.1172/JCI66204 Shin, 2011, Rapamycin and IL-2 reduce lethal acute graft-versus-host disease associated with increased expansion of donor type CD4+CD25+Foxp3+ regulatory T cells, Blood, 118, 2342, 10.1182/blood-2010-10-313684 Galipeau, 2013, The mesenchymal stromal cells dilemma—does a negative phase III trial of random donor mesenchymal stromal cells in steroid-resistant graft-versus-host disease represent a death knell or a bump in the road?, Cytotherapy, 15, 2, 10.1016/j.jcyt.2012.10.002 Laplante, 2012, mTOR signaling in growth control and disease, Cell, 149, 274, 10.1016/j.cell.2012.03.017 Houghton, 2010, Everolimus, Clin Cancer Res, 16, 1368, 10.1158/1078-0432.CCR-09-1314 Pessina, 2013, Mesenchymal stromal cells primed with Paclitaxel attract and kill leukaemia cells, inhibit angiogenesis and improve survival of leukaemia-bearing mice, Br J Haematol, 160, 766, 10.1111/bjh.12196 Singh, 2012, Regulatory T cells exhibit decreased proliferation but enhanced suppression after pulsing with sirolimus, Am J Transplant, 12, 1441, 10.1111/j.1600-6143.2011.03963.x Tisato, 2007, Mesenchymal stem cells of cord blood origin are effective at preventing but not treating graft-versus-host disease, Leukemia, 21, 1992, 10.1038/sj.leu.2404847 Gregoire-Gauthier, 2012, Therapeutic efficacy of cord blood-derived mesenchymal stromal cells for the prevention of acute graft-versus-host disease in a xenogenic mouse model, Stem Cells Dev, 21, 1616, 10.1089/scd.2011.0413 Bernardo, 2013, Mesenchymal stromal cells: sensors and switchers of inflammation, Cell Stem Cell, 13, 392, 10.1016/j.stem.2013.09.006 Battaglia, 2005, Rapamycin selectively expands CD4+CD25+FoxP3+ regulatory T cells, Blood, 105, 4743, 10.1182/blood-2004-10-3932 Akiyama, 2012, Mesenchymal-stem-cell-induced immunoregulation involves FAS-ligand-/FAS mediated T cell apoptosis, Cell Stem Cell, 10, 544, 10.1016/j.stem.2012.03.007 Jiang, 2014, CD4+CD25+ regulatory T cells are not required for mesenchymal stem cell function in fully MHC-mismatched mouse cardiac transplantation, Cell Tissue Res, 358, 503, 10.1007/s00441-014-1956-z